d22c9285-50cf-4724-9f81-606fb54c00fc
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 82
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.440
- DNA_REPAIR+0.400
- MYC_TARGETS_V2+0.400
- ADIPOGENESIS+0.360
- FATTY_ACID_METABOLISM+0.300
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.290
- BILE_ACID_METABOLISM+0.260
- E2F_TARGETS+0.230
- PEROXISOME+0.220
- MYC_TARGETS_V1+0.210
Top 10 suppressed
- TNFA_SIGNALING_VIA_NFKB-0.360
- MITOTIC_SPINDLE-0.350
- HEDGEHOG_SIGNALING-0.330
- INTERFERON_ALPHA_RESPONSE-0.320
- INTERFERON_GAMMA_RESPONSE-0.290
- UV_RESPONSE_DN-0.250
- TGF_BETA_SIGNALING-0.220
- G2M_CHECKPOINT-0.200
- APICAL_SURFACE-0.180
- KRAS_SIGNALING_UP-0.150
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | f844415e-ca2a-4837-b050-06775fdb2ed5 | — | — | 0.869 |
| 2 | d837c3e6-ef78-42a0-8a39-c57d48bc7c3a | — | — | 0.860 |
| 3 | e84aa97b-e429-4994-acef-2b57be71fe9a | — | — | 0.835 |
| 4 | efeb2328-6a31-4340-a086-c431a44348e1 | — | — | 0.813 |
| 5 | 0acddbbc-6b74-4fdd-903d-f5ec9bfd8514 | — | — | 0.802 |
| 6 | 4613d81b-e9ba-4c36-96a5-d7c9667b83ec | — | — | 0.798 |
| 7 | TCGA-A2-A3XV-01A-21R-A239-07 | — | B | 0.793 |
| 8 | C3N-01024 | — | cohortA1 | 0.779 |
| 9 | ERR2278870 | — | — | 0.773 |
| 10 | ERR2208902 | — | — | 0.770 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.440 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.400 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.400 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.360 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.300 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.290 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.260 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.230 | Inavolisib | — uncovered |
| PEROXISOME | 0.220 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.210 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.190 | Cobimetinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.190 | Inavolisib | — uncovered |
| COAGULATION | 0.160 | Binimetinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.150 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.110 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.090 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.070 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.060 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.040 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.040 | Inavolisib | — uncovered |